Zions Bancorporation N.A. Boosts Position in Kenvue Inc. (NYSE:KVUE)

Zions Bancorporation N.A. raised its stake in Kenvue Inc. (NYSE:KVUE) by 13.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 223,555 shares of the company’s stock after acquiring an additional 26,026 shares during the period. Zions Bancorporation N.A.’s holdings in Kenvue were worth $4,773,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Boston Partners lifted its position in Kenvue by 36.9% in the fourth quarter. Boston Partners now owns 23,595,963 shares of the company’s stock valued at $503,145,000 after acquiring an additional 6,366,097 shares during the last quarter. Holocene Advisors LP lifted its position in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after acquiring an additional 5,975,392 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Kenvue in the fourth quarter valued at $98,926,000. Finally, FMR LLC grew its holdings in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on KVUE shares. Barclays decreased their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday. They set an “in-line” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.85.

Kenvue Stock Up 0.3 %

Shares of Kenvue stock opened at $23.38 on Tuesday. The company has a market cap of $44.68 billion, a P/E ratio of 44.10, a PEG ratio of 2.62 and a beta of 1.25. The firm has a fifty day moving average of $22.13 and a two-hundred day moving average of $22.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.